Vir Biotechnology (VIR) Deferred Taxes (2018 - 2024)
Vir Biotechnology recorded quarterly Deferred Taxes of -$2.6 million in Q4 2024, down 4736.84% quarter-over-quarter from $57000.0 in Q3 2024, and down 148.64% year-over-year from $5.4 million in Q1 2024.
Vir Biotechnology's Deferred Taxes history runs 3 years deep, the most recent figure standing at -$2.6 million for Q4 2024.
- In Q4 2024, Deferred Taxes fell 148.64% year-over-year to -$2.6 million; the TTM figure through Dec 2024 stood at -$3.6 million (changed N/A YoY), while the FY2024 annual figure was -$2.9 million, down 177.42% from the prior year.
- Deferred Taxes came in at -$2.6 million for Q4 2024 at Vir Biotechnology, down from $57000.0 in the prior quarter.
- In the past five years, Deferred Taxes ranged from a high of $57000.0 in Q3 2024 to a low of -$2.6 million in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | -65.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 96.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 9.31 Mn |
| 10 | Vir Biotechnology | 1.33 Bn | 1.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -2.64 Mn |
| Sep 30, 2024 | 57,000.00 |
| Dec 31, 2023 | -1.06 Mn |
| Dec 31, 2018 | 980,000.00 |